Legend Biotech Appoints Ingrid Zhang as New CEO
Legend Biotech (LEGN) has announced the appointment of Ingrid Zhang as its new Chief Executive Officer, effective September 15, 2026. She will succeed Alan Bash, who served as interim CEO since July 2026. Zhang most recently held the position of Chief Commercial Officer at Novartis International, bringing extensive leadership and commercial experience to her new role. The change in leadership is expected to influence Legend Biotech's strategic direction and operational focus moving forward.
Tickers: $LEGN
Topics: Biotech Industry Leadership Change